To confirm sensitivity in other high mutational burden solid tumors, we evaluated MRD-EDGESNV LLOD in CRC and SCLC in in silico TF admixtures and found strong performance at low TFs (AUC of 0.80 at 1*10-5 in CRC, 0.86 at 5*10-6 in SCLC; Extended Data Fig. 2a-b, clinical detection sensitivity Extended Data Fig. 2c). This evidence concerns the gene TF and colorectal carcinoma.